



Omthera Contacts:

Douglas Carr
Financial Controller
Omthera Pharmaceuticals
908-741-4323
DCarr@Omthera.com

Omthera Media Relations:

Eric Goldman
Rx Communications Group
917-322-2563
egoldman@rxir.com

**Omthera Pharmaceuticals, Inc. to Present at the
BIO Windhover/Pharmaceutical Strategic Outlook 2011 Conference**

Bedminster, NJ, March 24, 2011 -- Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that Jerry Wisler, President and Chief Executive Officer, will present at the BIO Windhover/Pharmaceutical Strategic Outlook 2011 Conference at the Grand Hyatt in New York, on March 31, 2011 at 2:30pm ET.

About Omthera Pharmaceuticals, Inc.

Founded in 2008, Omthera Pharmaceuticals, Inc. is a privately-held, emerging specialty pharmaceuticals company focusing its efforts on the clinical development of new therapies for dyslipidemia. Led by a team of experts with exceptional experience in developing new therapies for lipid disorders, Omthera is dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease. The Company recently initiated a pivotal Phase III clinical trial for its lead product candidate, Epanova™, an Omega-3 fatty acid compound in development as a triglyceride-lowering adjunct therapy to diet in patients with very high triglycerides (≥ 500 mg/dL). Future planned clinical trials for Epanova include patients with high triglycerides (≥ 200 mg/dL and ≤ 500 mg/dL) currently on statin therapy. Omthera holds worldwide rights to Epanova under a license from Chrysalis Pharma AG, a privately held Swiss Company that is the owner of the product. For more information, please visit www.omthera.com.

###